ARQT vs TTRX
ARQT: Arcutis is a commercial-stage dermatology biotech company commercializing ZORYVE, a topical PDE4 inhibitor platform addressing psoriasis, atopic dermatitis, and seborrheic dermatitis across multiple age groups. TTRX: Turn Therapeutics is developing a non-systemic topical immunomodulator (GX-03) containing polyhexanide for moderate-to-severe eczema and onychomycosis, with topline results expected mid-2026.
Side-by-side fundamentals
| Metric | ARQT | TTRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.90 | $9.62 | |
| Market cap as of 2026-07-23 | $3.5B | $301M | |
| Net margin as of 2026-07-23 | -0.6% | n/a | |
| Gross margin as of 2026-07-23 | +90.9% | n/a | |
| Operating margin as of 2026-07-23 | +0.8% | n/a | |
| ROE as of 2026-07-23 | -1.4% | -117.3% | ARQT higher |
| ROA as of 2026-07-23 | -0.6% | -38.9% | ARQT higher |
| Debt / equity as of 2026-07-23 | 0.58 | 0.97 | ARQT lower |
| Revenue growth (YoY) as of 2026-07-23 | +95.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +367.3% | n/a | |
| Beta as of 2026-07-23 | 1.51 | 0.09 | |
| 1-year return as of 2026-07-22 close | +97.1% | +158.4% | TTRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.